• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 10:37:36 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMVT alert in real time by email
    SC 13G/A 1 form-sc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No. __2__)*

     

    Immunovant, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

     

    (Title of Class of Securities)

     

    45258J102

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [  ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No.

    45258J102

     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Investments, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0 
       
    6. SHARED VOTING POWER
       
     

    7,592,253*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    7,592,253*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    7,592,253*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    7.75% *

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN, OO, IA

     

     
     

     

    CUSIP No.

    45258J102

     

      

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Master Fund, Ltd.
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    5,300,729*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    5,300,729*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    5,300,729*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    5.41%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

     
     

     

    CUSIP No.

    45258J102

     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Roderick Wong
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    7,592,253*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    7,592,253*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    7,592,253*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    7.75%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    Item 1. (a).

    Name of Issuer:

     

    Immunovant, Inc.

         
         
      (b). Address of issuer’s principal executive offices:
         
        320 West 37th Street
        New York, NY 10018
         
         
    Item 2. (a). Name of person filing:
         
        RTW Investments, LP
        RTW Master Fund, Ltd.
        Roderick Wong
         
         
      (b). Address or principal business office or, if none, residence:
         
        RTW Investments, LP
        40 10th Avenue
        Floor 7
        New York, New York 10014
         
        RTW Master Fund, Ltd.
        c/o Intertrust Corporate Services (Cayman) Limited
        190 Elgin Avenue, George Town
        Grand Cayman KY1-9001, Cayman Islands
         
        Roderick Wong
        c/o RTW Investments, LP
       

    40 10th Avenue

        Floor 7
        New York, New York 10014
         
         
      (c). Citizenship:
         
        RTW Investments, LP – Delaware
        RTW Master Fund, Ltd. – Cayman Islands
        Roderick Wong – United States of America
         
         
      (d). Title of class of securities:
         
        Common Stock, $0.0001 par value
         
         
      (e). CUSIP No.:
         
        45258J102
         

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
       
      N/A
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
      (a) Amount beneficially owned:
           
          RTW Investments, LP – 7,592,253*
          RTW Master Fund, Ltd. – 5,300,729*
          Roderick Wong – 7,592,253*
           
             
      (b) Percent of class:
           
          RTW Investments, LP – 7.75% *
          RTW Master Fund, Ltd. – 5.41%*
          Roderick Wong – 7.75% *
           
           
      (c) Number of shares as to which the person has:
           
          (i) Sole power to vote or to direct the vote
             
            RTW Investments, LP – 0
            RTW Master Fund, Ltd. – 0
            Roderick Wong – 0
             
          (ii) Shared power to vote or to direct the vote
             
            RTW Investments, LP – 7,592,253*
            RTW Master Fund, Ltd. – 5,300,729*
            Roderick Wong – 7,592,253*
             
          (iii) Sole power to dispose or to direct the disposition of
             
            RTW Investments, LP – 0
            RTW Master Fund, Ltd. – 0
            Roderick Wong – 0
             
          (iv) Shared power to dispose or to direct the disposition of
             
            RTW Investments, LP – 7,592,253*
            RTW Master Fund, Ltd. – 5,300,729*
            Roderick Wong – 7,592,253*

     

     

     * The Common Stock, $0.0001 par value (the “Shares”), of Immunovant, Inc. (the “Company”) reported herein are held by RTW Master Fund, Ltd. and one or more private funds (together the “Funds”) managed by RTW Investments, LP (the “Adviser”). The Adviser, in its capacity as the investment manager of the Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 7,592,253 Shares, or 7.75% of the Company’s 97,890,705 Shares deemed issued and outstanding as of December 31, 2020. Roderick Wong is the Managing Partner of the Adviser. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

       
      N/A
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
       
    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     
      N/A
       
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 16, 2021    
         
      RTW Investments, LP
         
      By: /s/ Roderick Wong
        Roderick Wong, Managing Partner
         
      RTW Master Fund, Ltd.
         
      By: /s/ Roderick Wong
        Roderick Wong, Director
         
      Roderick Wong
         
      By: /s/ Roderick Wong
        Roderick Wong, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $IMVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMVT

    DatePrice TargetRatingAnalyst
    3/3/2025$20.00Hold
    Jefferies
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    10/10/2024$36.00Outperform
    Raymond James
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    3/28/2024$50.00Outperform
    Oppenheimer
    3/13/2024$50.00Buy
    Goldman
    2/20/2024$51.00Overweight
    JP Morgan
    2/15/2024$55.00Outperform
    Wolfe Research
    More analyst ratings

    $IMVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Girao Tiago was granted 208,388 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:09 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Susman Robert Graham was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:05 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bauer Jake was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:07 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    SEC Filings

    See more
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      5/19/25 4:40:29 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Immunovant Inc.

      S-8 - Immunovant, Inc. (0001764013) (Filer)

      4/30/25 4:06:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Immunovant Inc.

      SCHEDULE 13D/A - Immunovant, Inc. (0001764013) (Subject)

      4/21/25 7:54:01 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Immunovant Sciences with a new price target

      Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00

      3/3/25 7:24:04 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences downgraded by Wolfe Research

      Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform

      1/3/25 7:34:55 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Immunovant Sciences with a new price target

      Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00

      10/10/24 8:38:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $IMVT
    Leadership Updates

    Live Leadership Updates

    See more

    $IMVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

      3/19/25 7:45:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l

      3/18/25 4:32:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      11/12/24 10:32:13 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/14/24 8:47:41 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunovant Inc.

      SC 13G - Immunovant, Inc. (0001764013) (Subject)

      2/9/24 9:16:06 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Mark Levine as Chief Legal Officer

      Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

      1/25/22 8:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Renee Barnett as Chief Financial Officer

      Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

      9/15/21 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      1/15/25 4:36:38 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      10/4/23 5:15:20 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Financials

    Live finance-specific insights

    See more
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

      Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

      2/6/25 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

      Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

      11/7/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care